Shield Therapeutics logo

STX - Shield Therapeutics Share Price

34.88p 0.4  1.1%

Last Trade - 9:33am

Small Cap
Market Cap £74.5m
Enterprise Value £51.9m
Revenue £1.95m
Position in Universe 1115th / 1785
Unlock STX Revenue
Relative Strength (%)
1m -18.9%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -73.2%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 0.30 0.64 11.9 0.72 10.4 4.83 29.2
Balance Sheet
FINANCIAL BRIEF: : For the six months ended 30 June 2021, ShieldTherapeutics PLC revenues decreased 95% to £481K. Net losstotaled £7.3M vs. income of £3.1M. Revenues reflect Rest ofthe world segment decrease of 100% to £18K, United Kingdomsegment decrease from £23K to £0K. Net loss reflectsFeraccru segment loss totaling £4.3M vs. income of £3.7M,Unallocated segment loss increase from £1.3M to £3.3M, PT20segment loss increase of 53% to £61K.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for STX
Graphical History


STX Revenue Unlock STX Revenue

Net Income

STX Net Income Unlock STX Revenue

Normalised EPS

STX Normalised EPS Unlock STX Revenue

PE Ratio Range

STX PE Ratio Range Unlock STX Revenue

Dividend Yield Range

STX Dividend Yield Range Unlock STX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
STX EPS Forecasts Unlock STX Revenue
Profile Summary

Shield Therapeutics PLC is a specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals. The Company's product, Feraccru, is an oral treatment for iron deficiency anemia (IDA) in patients for whom intravenous iron or blood transfusions is needed. It also has a pipeline of over three prescription pharmaceutical assets, including PT20, PT30 and PT40. PT20, which is in Phase II clinical trials, is used as a treatment for hypophosphatemia. PT30, which indicates advanced intravenous (IV) iron formulation, is in pre-clinical stage. Its PT40, which indicates generic IV iron formulation, is in pre-clinical trials. Feraccru, which indicates IDA in chronic kidney disease (CKD) and inflammatory bowel disease (IBD), is in Phase III clinical trials. Its other indications for Feraccru are in Phase II clinical trials.

Last Annual December 31st, 2020
Last Interim June 30th, 2021
Incorporated September 3, 2015
Public Since February 26, 2016
No. of Shareholders: n/a
No. of Employees: 16
Sector Healthcare
Industry Biotechnology & Medical Research
Index FTSE Aim All Share ,
Exchange London Stock Exchange (AIM)
Shares in Issue 215,874,000
Free Float (0.0%)
Eligible for
STX Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for STX
Upcoming Events for STX
Frequently Asked Questions for Shield Therapeutics
What is the Shield Therapeutics share price?

As of 9:33am, shares in Shield Therapeutics are trading at 34.88p, giving the company a market capitalisation of £74.5m. This share price information is delayed by 15 minutes.

How has the Shield Therapeutics share price performed this year?

Shares in Shield Therapeutics are currently trading at 34.88p and the price has moved by -72.79% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Shield Therapeutics price has moved by -78.63% over the past year.

What are the analyst and broker recommendations for Shield Therapeutics?

Of the analysts with advisory recommendations for Shield Therapeutics, there are there are currently 1 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Shield Therapeutics is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Shield Therapeutics next release its financial results?

Shield Therapeutics is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2022-06-30
What is the Shield Therapeutics dividend yield?

Shield Therapeutics does not currently pay a dividend.

Does Shield Therapeutics pay a dividend?

Shield Therapeutics does not currently pay a dividend.

When does Shield Therapeutics next pay dividends?

Shield Therapeutics does not currently pay a dividend.

How do I buy Shield Therapeutics shares?

To buy shares in Shield Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Shield Therapeutics?

Shares in Shield Therapeutics are currently trading at 34.88p, giving the company a market capitalisation of £74.5m.

Where are Shield Therapeutics shares listed? Where are Shield Therapeutics shares listed?

Here are the trading details for Shield Therapeutics:

Country of listing: United Kingdom
Exchange: LSE
Ticker Symbol: STX
What kind of share is Shield Therapeutics?

Based on an overall assessment of its quality, value and momentum, Shield Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Shield Therapeutics share price forecast 2021?

Shares in Shield Therapeutics are currently priced at 34.88p. At that level they are trading at 0.639% discount to the analyst consensus target price of 35.10.

Analysts covering Shield Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -0.08722 for the next financial year.

How can I tell whether the Shield Therapeutics share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Shield Therapeutics. Over the past six months, the relative strength of its shares against the market has been -30.17%. At the current price of 34.88p, shares in Shield Therapeutics are trading at -25.83% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Shield Therapeutics PE Ratio?

We were not able to find PE ratio data for Shield Therapeutics.

Who are the key directors of Shield Therapeutics?

Shield Therapeutics's management team is headed by:

Peter Llewellyn-Davies - NID
Hans Hasler - NEC
Tim Watts - EDR
Christian Schweiger - NED
Hans-Peter Rudolf - CFO
Fabiana Lacerca-Allen - NID
Anders Lundstrom - NID
Gregory Madison - CEO
Jose Menoyo - VPR
Who are the major shareholders of Shield Therapeutics?

Here are the top five shareholders of Shield Therapeutics based on the size of their shareholding:

W. Health L.P. Corporation
Percentage owned: 25.95% (56.0m shares)
LGT Bank (Schweiz) AG Bank and Trust
Percentage owned: 13.3% (28.7m shares)
AOP Orphan International AG Corporation
Percentage owned: 13.13% (28.3m shares)
Jupiter Asset Management Ltd. Investment Advisor/Hedge Fund
Percentage owned: 5.61% (12.1m shares)
Jupiter UK Smaller Companies Equity Fund Mutual Fund
Percentage owned: 5.61% (12.1m shares)
Similar to STX
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.